Integrins are activated by signaling from inside the cell (inside-out signaling) through global conformational changes of integrins. We recently discovered that fractalkine activates integrins in the absence of CX3CR1 through the direct binding of fractalkine to a ligand-binding site in the integrin headpiece (site 2) that is distinct from the classical RGD-binding site (site 1). We propose that fractalkine binding to the newly identified site 2 induces activation of site 1 though conformational changes (in an allosteric mechanism). We reasoned that site 2-mediated activation of integrins is not limited to fractalkine. Human secreted phospholipase A2 type IIA (sPLA2-IIA), a proinflammatory protein, binds to integrins ␣v␤3 and ␣4␤1 (site 1), and this interaction initiates a signaling pathway that leads to cell proliferation and inflammation. Human sPLA2-IIA does not bind to M-type receptor very well. Here we describe that sPLA2-IIA directly activated purified soluble integrin ␣v␤3 and transmembrane ␣v␤3 on the cell surface. This activation did not require catalytic activity or M-type receptor. Docking simulation predicted that sPLA2-IIA binds to site 2 in the closed-headpiece of ␣v␤3. A peptide from site 2 of integrin ␤1 specifically bound to sPLA2-IIA and suppressed sPLA2-IIA-induced integrin activation. This suggests that sPLA2-IIA activates ␣v␤3 through binding to site 2. sPLA2-IIA also activated integrins ␣4␤1 and ␣5␤1 in a site 2-mediated manner. We recently identified small compounds that bind to sPLA2-IIA and suppress integrin-sPLA2-IIA interaction (e.g. compound 21 (Cmpd21)).
Cmpd21 effectively suppressed sPLA2-IIA-induced integrin activation. These results define a novel mechanism of proinflammatory action of sPLA2-IIA through integrin activation.
Secreted PLA2 type IIA (sPLA2-IIA) 2 was first isolated and purified from rheumatoid synovial fluid (1) . sPLA2-IIA is an acute phase reactant, and its plasma concentration markedly increases in diseases that involve systemic inflammation such as sepsis, rheumatoid arthritis, and cardiovascular disease (up to 1000-fold and Ͼ1 g/ml). Inflammatory cytokines such as IL-6, TNF-␣, and IL-1␤ induce synthesis and release of sPLA2-IIA in arterial smooth muscle cells and hepatocytes, which are the major sources of the plasma sPLA2-IIA in these systemic inflammatory conditions (2, 3) . In addition to being a proinflammatory protein, sPLA2-IIA expression is elevated in neoplastic prostatic tissue (4) , and dysregulation of sPLA2-IIA may play a role in prostatic carcinogenesis (5) and is a potential therapeutic target in prostate cancer (6) .
Notably some biological effects associated with sPLA2-IIA are independent of its catalytic function (7) . Catalytically inactive sPLA2-IIA mutants retain the ability to enhance cyclooxygenase-2 expression in connective tissue mast cells (7) . Also, inactivation of sPLA2-IIA by bromophenacyl bromide does not affect the ability of sPLA2-IIA to induce secretion of ␤-glucuronidase, IL-6, and IL-8 from human eosinophils (8) . It has thus been proposed that sPLA2-IIA action is mediated through interaction with specific receptors. Indeed the enzyme binds to a high affinity receptor of 180 kDa present on rabbit skeletal muscle (9) . This so-called M (muscle)-type receptor belongs to the superfamily of C-type lectins and mediates some of the physiological effects of mammalian sPLA2-IIA, and binding of sPLA2-IIA to this receptor induces internalization of sPLA2-IIA (10) . However, the interaction between sPLA2-IIA and the M-type receptor is species-specific, and human sPLA2-IIA binds to the human or mouse M-type receptor very weakly (11) .
Integrins are a family of cell adhesion receptors that recognize ECM ligands and cell surface ligands (12) . Integrins are transmembrane heterodimers, and at least 18 ␣ and 8 ␤ subunits are known (13) . Integrins transduce signals to the cell upon ligand binding (12) . We previously reported that sPLA2-IIA specifically binds to integrins ␣v␤3 and ␣4␤1 and induces proliferative signals in an integrin-dependent manner. sPLA2-IIA specifically binds to integrin v3 and 41 (14) . The integrinbinding site does not include the catalytic center or the M-type receptor-binding site. WT and the catalytically inactive mutant (the H47Q mutant) of sPLA2-IIA induce intracellular signals in monocytic cells, but an integrin binding-defective mutant (the R74E/R100E mutant) does not (14) . These results suggest that integrins may serve as receptors for sPLA2-IIA and mediate proinflammatory action of sPLA2-IIA in human. We screened small compounds that bind to sPLA-IIA and inhibit integrin binding. We obtained several compounds and compound 21 (Cmpd21) suppresses ␣v␤3-mediated cell adhesion and migration (15) . These findings indicate direct binding of sPLA2-IIA to integrins is critical for proinflammatory actions of sPLA2-IIA.
It has been proposed that integrin activation is mediated by signaling from inside the cell (inside-out signaling) and that integrin activation is associated with global conformational changes of the integrin molecule (16, 17) . We recently discovered that the chemokine domain of fractalkine (FKN-CD) directly binds to several integrins, and this interaction is critical for fractalkine/CX3CR1 signaling (18) . FKN-CD induces ternary complex formation (integrin-FKN-CD-CX3CR1) on the cell surface, suggesting that integrins act as the co-receptor for FKN-CD in FKN/CX3CR1 signaling (18) . Notably we discovered that FKN-CD can activate integrins in the absence of CX3CR1 through direct binding to integrins probably in an allosteric mechanism (19) . We identified a new FKN-CD-binding site in integrins (site 2) that is distinct from the classical RGD-binding site (site 1). The position of site 2 was predicted by docking simulation of interaction between FKN-CD and integrin ␣v␤3 that has a closed-headpiece conformation. This is based on the premise that site 2 is open in the closed-headpiece ␣v␤3. A peptide from site 2 (residues 267-286 of ␤3) directly binds to FKN-CD and suppresses FKN-CD-induced integrin activation (19) . We thus propose a model in which FKN-CD binding to site 2 induces activation of site 1 though conformational changes (in an allosteric mechanism).
The site 2-mediated activation of integrins may not be limited to FKN-CD. In the present paper we describe that sPLA2-IIA directly activates integrins (␣v␤3, ␣4␤1, and ␣5␤1) in cellfree conditions and/or on the cell surface. sPLA2-IIA mutants that are catalytically inactive or defective in binding to the M-type receptor still activate integrins, whereas the integrin binding-defective mutant did not. This suggests that direct integrin binding is required, but catalytic activity or M-type receptor is not. sPLA2-IIA is predicted to bind to site 2 in ␣v␤3 in a closed-headpiece conformation in docking simulation. Consistently, we obtained evidence that a peptide from site 2 effectively suppressed the sPLA-IIA-induced integrin activation, suggesting that this activation involves the binding of sPLA-IIA to site 2. Cmpd21 effectively suppressed sPLA2-IIAinduced integrin activation. These results define a novel mechanism of proinflammatory action of sPLA2-IIA through integrin activation.
EXPERIMENTAL PROCEDURES
Materials-U937 monocytic cells and Chinese hamster ovary (CHO) cells were obtained from the American Type Culture Collection. K562 erythroleukemia cells that express human integrin ␣v␤3 (␣v␤3-K562) (20) were provided by Eric Brown (University of California, San Francisco, CA). K562 cells that express human integrin ␣4 (␣4-K562), CHO cells that express human integrin ␤3 (␤3-CHO), or integrin ␣4 (␣4-CHO) were described (14) . Recombinant soluble ␣v␤3 was synthesized in CHO-K1 cells using the soluble ␣v and ␤3 expression constructs and purified by nickel-nitrilotriacetic acid affinity chromatography as described (21) . Fibrinogen ␥-chain C-terminal domain that lacks residues 400 -411 (␥C399tr) was synthesized as described (22) . Fibronectin H120 fragment (FN-H120) (18) , fibronectin type III domains 8 -11 (FN8 -11) (19) , and ADAM15 (23) were synthesized as GST fusion proteins as described in the cited references. Anti-human ␤3 mAb AV10 was provided by B. Felding-Habermann (The Scripps Research Institute, La Jolla, CA). HRP-conjugated anti-His tag antibody was purchased from Qiagen (Valencia, CA). Cmpd21 was synthesized as described (15) .
Synthesis of sPLA2-IIA-Recombinant sPLA2-IIA proteins (WT and mutants) were synthesized as described (14) using PET28a expression vector. The proteins were synthesized in Escherichia coli BL21 and induced by isopropyl ␤-D-thiogalactoside as insoluble proteins. The proteins were solubilized in 8 M urea, purified by nickel-nitrilotriacetic acid affinity chromatography under denatured conditions, and refolded as previously described (14) . The refolded proteins were Ͼ90% homogeneous upon SDS-PAGE.
Synthesis of Site 2 Peptides-We introduced a His 6 tag to the BamHI site of pGEX-2T using 5Ј-GATCTCATCATCACCAT-CACCATG-3Ј and 5Ј-GATCCATGGTGATGGTGATGA-TGA-3Ј (the resulting vector is designated pGEX-2THis 6 ). We synthesized GST fusion protein of site 2 peptide (QPNDGQS-HVGSDNHYSASTTM, residues 267-287 of ␤3, Cys-273 is changed to S) and a scrambled site 2 peptide (VHDSHYSGQ-GAMSDNTNSPQT) by subcloning oligonucleotides that encode these sequences into the BamHI/EcoRI site of pGEX-2THis 6 . We synthesized the proteins in E. coli BL21 and purified using glutathione-Sepharose affinity chromatography (18) . The corresponding ␤1, ␤2, and ␤4 peptides were generated as described (18) .
Binding of Soluble ␣v␤3 to ␥C399tr-ELISA-type binding assays were performed as described previously (18) . Briefly, wells of 96-well Immulon 2 microtiter plates (Dynatech Laboratories, Chantilly, VA) were coated with 100 l of 0.1 M NaHCO 3 containing ␥C399tr or ADAM15 for 2 h at 37°C.
Remaining protein-binding sites were blocked by incubating with PBS, 0.1% BSA for 30 min at room temperature. After washing with PBS, soluble recombinant ␣v␤3 (5 g/ml) in the presence or absence of sPLA2-IIA (WT or mutants) was added to the wells and incubated in HEPES-Tyrodes buffer (10 mM HEPES, 150 mM NaCl, 12 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 2.5 mM KCl, 0.1% glucose, 0.1% BSA) with 1 mM CaCl 2 for 2 h at room temperature. After unbound ␣v␤3 was removed by rinsing the wells with binding buffer, bound ␣v␤3 was measured using anti-integrin ␤3 mAb (AV-10) followed by HRP-conjugated goat anti-mouse IgG and peroxidase substrates.
Binding of Labeled Ligands to Integrins on the Cell Surface-The cells were cultured to nearly confluent in RPMI 1640, 10% FCS (K562 and U937) or DMEM, 10% FCS (CHO cells). The cells were resuspended with RPMI 1640, 0.02% BSA or DMEM, 0.02% BSA and incubated for 30 min at room temperature to block the remaining protein-binding sites. The cells were then incubated with WT sPLA2-IIA or mutants for 5 min at room temperature and then incubated with FITC-labeled integrin ligands (␥C399tr, FN-H120, FN8 -11, and ADAM15) for 15 min at room temperature. For blocking experiments, sPLA-IIA was preincubated with S2-␤1 peptide for 30 min at room temperature. The cells were washed with PBS, 0.02% BSA and analyzed by FACSCalibur (BD Biosciences). For inhibition studies using Cmpd21, sPLA2-IIA was preincubated with Cmpd21 for 30 min at room temperature.
Binding of S2 Peptide to Proteins-ELISA-type binding assays were performed as described previously (18) . Briefly, wells of 96-well Immulon 2 microtiter plates (Dynatech Laboratories, Chantilly, VA) were coated with 100 l of 0.1 M NaHCO 3 containing sPLA2-IIA, ␥C399tr, and FN-H120 for 2 h at 37°C. The remaining protein-binding sites were blocked by incubating with PBS, 0.1% BSA for 30 min at room temperature. After washing with PBS, S2 peptides were added to the wells and incubated in PBS for 2 h at room temperature. After unbound S2 peptides were removed by rinsing the wells with PBS, bound S2 peptides (GST-tagged) were measured using HRP-conjugated anti-GST antibody and peroxidase substrates.
Adhesion Assays-Adhesion assays were performed as described previously (18) . Briefly, wells of a 96-well Immulon 2 microtiter plates were coated with 100 l of 0.1 M NaHCO 3 containing sPLA2-IIA (10 g/ml) and were incubated for 2 h at 37°C. The remaining protein-binding sites were blocked by incubating with PBS, 0.1% BSA for 30 min at room temperature. After washing with PBS, ␣4-K562 or K562 cells in 100 l of RPMI 1640 were added to the wells and incubated at 37°C for 1 h in the presence of Cmpd21 (0 -100 M). After unbound cells were removed by rinsing the wells with RPMI 1640, bound cells were quantified by measuring endogenous phosphatase activity.
Chemotaxis-Chemotaxis was measured in modified Boyden Chambers (Transwell). One g/ml sPLA2-IIA and 20 g/ml S2-␤1 peptide or control peptides in 600 l of RPMI 1640 medium were placed in the lower chamber, and U937 cells (2 ϫ 10 5 cells in 100 l of RPMI1640 medium) were placed in the upper chamber. After 5 h of incubation at 37°C, cells in the lower chamber were counted.
Docking Simulation-Docking simulation of interaction between sPLA2-IIA (PDB code 1DCY), and integrin ␣v␤3 was performed using AutoDock3 as described (24) . In the present study we used the headpiece (residues 1-438 of ␣v and residues 55-432 of ␤3) of ␣v␤3 (closed-headpiece form, PDB code 1JV2). Cations were not present in ␣v␤3 during docking simulation, as in the previous studies using ␣v␤3 (open-headpiece form, PDB code 1L5G) (14, 24) .
Other Methods-Treatment differences were tested using analysis of variance and a Tukey multiple comparison test to control the global type I error using Prism 5.0 (Graphpad Software). Surface plasmon resonance studies were performed as described (18) .
RESULTS
sPLA2-IIA Activates Soluble Integrin ␣v␤3 in Cell-free Conditions-We recently reported that FKN-CD can activate integrins in the absence of CX3CR1 through direct binding to site 2 of integrins (19) . A peptide from site 2 of integrin ␤3 (S2-␤3 peptide) directly binds to FKN-CD and suppresses FKN-CDinduced integrin activation (19) . The newly identified site 2 is distinct from the classical RGD-binding site (site 1). We propose that FKN-CD binding to site 2 induces activation of site 1 through conformational changes (in an allosteric mechanism). The site 2-mediated activation of integrins may not be limited to FKN-CD, and we tested if other known integrin ligands activate ␣v␤3.
We previously reported that sPLA2-IIA binds to integrins ␣v␤3 and ␣4␤1 and induces signals through integrin pathways (14) . We studied if sPLA2-IIA enhances the binding of recombinant soluble ␣v␤3 to ␥C399tr, an ␣v␤3-specific ligand (22, 25) in cell-free conditions. We immobilized ␥C399tr to wells of microtiter plates and measured the binding of soluble ␣v␤3 to ␥C399tr in the presence of sPLA2-IIA. To keep soluble integrin inactive, we included 1 mM Ca 2ϩ in the assay. WT sPLA2-IIA enhanced the binding of ␥C399tr to ␣v␤3 in a concentrationdependent manner (Fig. 1, a and b) . In contrast to WT sPLA2-IIA, the R74E/R100E mutant (integrin-binding-defective) (14) was defective in this function ( Fig. 1b ). H47Q (catalytically inactive) and G29S/D48K (M-type receptor-binding-defective) mutants behaved like WT sPLA2-IIA ( Fig. 1c ). These findings suggest that sPLA2-IIA activates ␣v␤3 in cell-free conditions, and this activation requires the integrin-binding site of sPLA2-IIA but does not require catalytic activity or receptor binding.
We studied if sPLA2-IIA activates integrins on the cell surface by measuring the binding of FITC-labeled ␥C399tr to cells using flow cytometry. WT sPLA2-IIA activated ␣v␤3 on U937 (␣v␤3ϩ) ( Fig. 1d ), K562 cells that express recombinant ␣v␤3 (␣v␤3-K562 cells) (Fig. 1e ), and CHO cells that express hamster ␣v/human ␤3 hybrid (␤3-CHO cells) (Fig. 1f ). The effects of sPLA2-IIA mutations on sPLA2-IIA-induced ␣v␤3 activation were similar to those in soluble ␣v␤3. These findings suggest that sPLA2-IIA activates ␣v␤3 on the cell surface in a manner similar to that of soluble ␣v␤3 and that the sPLA2-IIA-induced ␣v␤3 activation is not cell type-specific.
It is possible that the effect of sPLA2-IIA on ␣v␤3 may be specific to ␥C399tr. We thus used the disintegrin domain of human ADAM15, which has an RGD motif and specifically FIGURE 1. sPLA2-IIA activates ␣v␤3 integrin in cell-free conditions and on the cell surface (through direct integrin binding). a, activation of soluble ␣v␤3 by sPLA2-IIA as a function of ␥C399tr concentration. Binding of soluble ␣v␤3 (5 g/ml) to immobilized ␥C399tr in the presence or absence of WT sPLA2-IIA (50 g/ml) was performed as described under "Experimental Procedures." Data are shown as the means Ϯ S.E. of three independent experiments. b, activation of soluble ␣v␤3 by sPLA2-IIA as a function of sPLA2-IIA concentration. Wells of 96-well microtiter plates were coated with ␥C399tr (100 g/ml) and incubated with soluble ␣v␤3 (5 g/ml). Data are shown as the means Ϯ S.E. of three independent experiments. c, the effects of sPLA2-IIA mutations on integrin ␣v␤3 activation. Activation of soluble ␣v␤3 was measured as described above. SPLA2-IIA (50 g/ml) and ␥C399tr (100 g/ml for coating) were used. R74E/R100E, defective in integrin binding; H74Q, catalytically inactive; G29S/D48K, defective in the binding to M-type receptor. d-f, the effects of sPLA2-IIA mutations on the binding of ␥C399tr to integrin ␣v␤3 on the cell surface. The binding of FITC-labeled ␥C399tr to the cells in the presence of sPLA2-IIA (up to 20 g/ml in the case of U937 cells (d) and 20 g/ml in ␣v␤3-K562 (e) and ␤3-CHO (f) cells) was measured using flow cytometry as described under "Experimental Procedures." Data are shown as the means (median fluorescent intensity (MFI)) Ϯ S.E. of three independent experiments. g and h, the effects of sPLA2-IIA mutations on the binding of ADAM15 to integrin ␣v␤3. The binding of FITC-labeled ADAM15 to ␣v␤3 in the presence of sPLA2-IIA (20 g/ml) in ␣v␤3-K562 (g) and ␤3-CHO (h) cells was measured using flow cytometry. Data are shown as means (median fluorescent intensity) Ϯ S.E. of three independent experiments.
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binds to ␣v␤3 (23) . The binding of FITC-labeled ADAM15 disintegrin domain was markedly enhanced by WT sPLA2-IIA, but not by R74E/R100E, in ␣v␤3-K562 ( Fig. 1g ) and ␤3-CHO cells (Fig. 1h ), suggesting that the effect of sPLA2-IIA on the ligand binding to ␣v␤3 is not unique to ␥C399tr. We confirmed that sPLA2-IIA does not directly interact with the integrin ligands used in this study (supplemental Fig. S1 ). sPLA2-IIA directly binds to integrins.
Docking Simulation Predicts That sPLA2-IIA Binds to Site 2 in an Inactive Form of ␣v␤3-We studied if sPLA2-IIA-induced activation of ␣v␤3 involves the binding of sPLA2-IIA to site 2 of ␣v␤3. Docking simulation of the interaction between sPLA2-IIA and the closed-headpiece form of ␣v␤3 (PDB code 1JV2) predicts that sPLA2-IIA binds to site 2 with high affinity (docking energy Ϫ22.1 kcal/mol) ( Fig. 2a ) as in the case of FKN-CD (19) . Site 2 is located at the opposite side of site 1 (Fig. 2, b and  c) . The RGD peptide binds to site 1 in the open-headpiece ␣v␤3 (Fig. 2d ). Amino acid residues in sPLA2-IIA and integrin ␣v␤3 that are involved in sPLA2-IIA-␣v␤3 integrin are listed in Table  1 . The docking model predicts that Arg-74 and Arg-100 are within the sPLA2-IIA/␣v␤3 interface at site 2 (Fig. 1a) , suggesting that the integrin-binding interface in sPLA2-IIA at site 2 overlaps with that of site 1. This predicts that sPLA2-IIA may activate integrins through direct binding to site 2 and that the R74E/R100E mutant may be defective in this function.
sPLA2-IIA Directly Binds to a Peptide Derived from Site 2 of Integrin ␤1-We previously identified a peptide sequence (e.g. residues 256 -288 of ␤3, S2-␤3 peptide) from site 2 of ␣v␤3 that directly interacts with FKN-CD (Fig. 3a) . The peptide suppresses FKN-CD-mediated integrin activation, but control scrambled peptide does not (19) . We studied if site 2-derived peptides bind to sPLA2-IIA. It was expected that S2-␤3 peptide binds to sPLA2-IIA because the amino acid residues in S2-␤3 peptide are located within the integrin-binding interface of sPLA2-IIA in the docking model (Table 1) . Interestingly, site 2 peptides from ␤1 (S2-␤1 peptide) bound better to sPLA2-IIA in a concentration-dependent manner than S2-␤3 peptide (Fig. 3,  b and c) . Control GST or scrambled S2-␤3 peptide (S2-␤3scr) did not bind to sPLA2-IIA. This suggests that site 2 has different binding specificity to FKN-CD and sPLA2-IIA. S2-␤1 peptide suppressed sPLA2-IIA-mediated ␣v␤3 activation in U937 (Fig.  3d ), ␣v␤3-K562 (Fig. 3e) , and ␤3-CHO ( Fig. 3f ) cells, whereas control GST or S2-␤3scr peptide did not. These findings suggest that sPLA2-IIA binds specifically to site 2 and that the binding of sPLA2-IIA to site 2 is critical for sPLA2-IIA-mediated ␣v␤3 activation.
sPLA2-IIA Activates ␣4␤1 in a Site 2-dependent Manner-We have reported that sPLA2-IIA directly binds to another integrin, ␣4␤1, and induces signals in an ␣4␤1-dependent manner (14) . We found that sPLA2-IIA enhanced the binding of FITC-labeled fibronectin fragment specific to ␣4␤1 (H120) to U937 cells (␣4ϩ) (Fig. 4a ), K562 cells that express recombinant ␣4 (␣4-K562) (Fig. 4c) , and CHO cells that express recombinant ␣4 (␣4-CHO) (Fig. 4e ). This suggests that sPLA2-IIA activates FIGURE 2. Docking simulation predicts that sPLA2-IIA binds to a binding site that is distinct from the classical RGD-binding site in closed-headpiece ␣v␤3. a, a docking model of sPLA2-IIA-integrin ␣v␤3 (inactive) interaction. The headpiece of an inactive form of integrin ␣v␤3 (PDB code 1JV2) was used as a target. b, a docking model of sPLA2-IIA-integrin ␣v␤3 (active) interaction (14) . The headpiece of the ligand-bound form of integrin ␣v␤3 (PDB code 1L5G) was used as a target. The model predicts that sPLA2-IIA (PDB code 1DCY) binds to the classical RGD-binding site of the integrin ␣v␤3 headpiece (Site 1). The model predicts the position of the second sPLA2-IIA-binding site (Site 2). c, superposition of two models shows that the positions of two predicted sPLA2-IIA-binding sites are distinct. d, open-headpiece ␣v␤3 structure (PDB code 1L5G) with an RGD-containing peptide (Site 1).
TABLE 1 Amino acid residues involved in the interaction between sPLA2-IIA and integrin ␣v␤3
Amino acid residues within 6 Å between sPLA2-IIA and ␣v␤3 were selected using pdb viewer (Version 4.1). Amino acid residues in ␤3 site 2 peptide (S2-␤3) are shown in bold.
␣v ␤3 sPLA2-IIA sPLA2-IIA Activates Integrins ␣4␤1 . WT sPLA2-IIA markedly increased the binding of H120 to ␣4␤1, whereas R74E/R100E did not ( Fig. 4, a, c, and e) . The H47Q or G29S/D48K mutants induced ␣4␤1 activation, like WT sPLA2-IIA, suggesting that catalytic activity or receptor binding of sPLA2-IIA is not important. S2-␤1 peptide suppressed the binding of H120 to ␣4␤1 increased by sPLA2-IIA, whereas control GST or S2-␤3scr peptide did not ( Fig. 4, b, d , and e). These results suggest that sPLA2-IIA activates integrin ␣4␤1 through direct binding to site 2 in a manner similar to that of ␣v␤3. Cmpd21 That Binds to sPLA2-IIA Inhibits sPLA2 IIA-mediated ␣v␤3 and ␣4␤1 Activation-We recently identified small compounds that bind to sPLA2-IIA and suppress sPLA2-IIA binding to ␣v␤3 (15), including Cmpd21 (Fig. 5a ). Cmpd21 was selected because of its ability to bind to WT sPLA2-IIA but not to R74E/R100E (15) . Cmpd21 binds to the integrin-binding site 
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of sPLA2-IIA and suppresses adhesion of ␣v␤3-K562 cells to ␥C399tr (15) . Consistently, Cmpd21 suppressed the binding of sPLA2-IIA to ␣v␤3 in a concentration-dependent manner in surface plasmon resonance studies (Fig. 5b) . We found that Cmpd21 suppressed the ␥C399tr binding to ␣v␤3-K562, U937, and ␤3-CHO cells in a concentration-dependent manner in three different cell types (Fig. 5, c, d, and e) . Cmpd21 also suppressed the adhesion of ␣4-K562 cells to sPLA2-IIA in a concentration-dependent manner (Fig. 6a ), suggesting that the effect of Cmpd21 is not limited to sPLA2-IIA-␣v␤3 interaction. Cmpd21 suppressed sPLA2-IIA-induced binding of H120 to ␣4␤1 in three different cell types (Fig. 6, b-d) . These findings suggest that Cmpd21 suppresses sPLA2-IIA-mediated ␣v␤3 and ␣4␤1 activation through site 2 by binding to the integrinbinding site of sPLA2-IIA.
sPLA2-IIA Enhances the Binding of the Fibronectin Fragment That Contains the RGD Motif to ␣5␤1-The interaction between the RGD-containing cell-binding fibronectin type III . sPLA2-IIA enhances the binding of the fibronectin fragment that contains CS-1 (H120) to ␣4␤1 through binding to site 2. a, sPLA2-IIA activates ␣4␤1. The binding of FITC-labeled FN H120 fragment (an ␣4␤1-specific ligand) to ␣4␤1 on U937 cells was measured by flow cytometry. WT sPLA2-IIA, catalytically inactive mutant (H47A), and the receptor-binding mutant (G29S/D48K) enhance the binding of H120 to ␣4␤1, but the integrin-binding defective mutant (R74E/R100E) does not. Data are shown as the means Ϯ S.E. of median fluorescent intensity (MFI) of three independent experiments. b, site 2 peptide from ␤1 (S2-␤1) suppressed sPLA2-IIA-induced ␣4␤1 activation in U937 cells (20 g/ml WT sPLA2-IIA was used). Data are shown as the means Ϯ S.E. of median fluorescent intensity of three independent experiments. c, d, and e, sPLA2-IIA mutations and S2-␤1 peptide affect ␣4␤1 activation by sPLA2-IIA in ␣4-K562 (c and d) and ␣4-CHO (e) cells. The binding of FITC-labeled FN H120 fragment to ␣4␤1ϩ cells was measured by flow cytometry. sPLA2-IIA (20 g/ml) and site 2 peptides (200 g/ml) were used. Data are shown as the means Ϯ S.E. of median fluorescent intensity of three independent experiments.
fragment and integrins has been extensively studied as a prototype cell-extracellular matrix interaction. We decided to study if sPLA2-IIA enhances the binding of this fragment to integrin ␣5␤1 using rat FN8 -11. We thus studied FN8 -11 binding to ␣5␤1. We found that sPLA2-IIA bound to integrin ␣5␤1 in K562 cells, in which ␣5␤1 is the only ␤1 integrin, and that mAb KH72 specific to ␣5 suppressed the binding, suggesting that sPLA2-IIA is a ligand of ␣5␤1 (Fig. 7a ). The binding of sPLA2-IIA to U937 cells was suppressed by KH73 (anti-␣5), 7E3 (anti-␣v␤3), and SG73 (anti-␣4), suggesting ␣v␤3 and ␣4␤1, in addition to ␣5␤1, are involved in sPLA2-IIA binding to U937 cells (Fig. 7b ). Cmpd21 effectively suppressed the adhesion of K562 cells to sPLA2-IIA (Fig. 7c) . These findings suggest that sPLA2-IIA interacts with ␣5␤1. We discovered that sPLA2-IIA markedly increased the binding of FITC-labeled FN8 -11 to ␣5␤1 on U937, K562, and CHO cells, whereas R74E/R100E did not (Fig.   7, d-f) . The H47Q or G29S/D48K mutants induced ␣5␤1 activation, like WT sPLA2-IIA. These findings suggest that sPLA2-IIA activates integrin ␣5␤1 and that catalytic activity or receptor binding of sPLA2-IIA is not required for this process, as in the case of ␣v␤3 and ␣4␤1. S2-␤1 peptide suppressed the binding of FN8 -11 to ␣5␤1, increased by sPLA2-IIA, whereas control GST or scrambled ␤3 peptide did not ( Fig. 7, g-i) . Cmpd21 suppressed sPLA2-IIA-induced binding of FN8 -11 to ␣5␤1 in three different cell types (Fig. 7, j-l) , suggesting Cmpd21 suppresses sPLA2-IIA-induced ␣5␤1 activation through site 2 as well. Taken together, these results suggest that sPLA2-IIA enhances FN8 -11 to integrin ␣5␤1 through direct binding of sPLA2-IIA to site 2, as in the case of ␣v␤3 and ␣4␤1.
sPLA2-IIA Suppresses H120 Binding to ␣4␤1 at High Concentrations-If sPLA2-IIA binds to site 1 (14) and site 2 (the present study), it is predicted that sPLA2-IIA competes with FIGURE 5. Cmpd21 blocks the binding of ␥C399tr to ␣v␤3 on the cell surface through binding to site 2. The effect of Cmpd21 on the binding of ␥C399tr to ␣v␤3 and on the sPLA2-IIA-induced integrin activation was studied. a, structure of Cmpd21. Amino acids with asterisks are D isomers. b, Cmpd21 suppresses the binding of sPLA2-IIA to ␣v␤3. Soluble ␣v␤3 was immobilized to a sensor chip, and Cmpd21 was added to the solution phase together with sPLA2-IIA in a surface plasmon resonance study. c-e, Cmpd21 suppressed the binding of FITC-labeled ␥C399tr enhanced by sPLA2-IIA (20 g/ml) to ␣v␤3 on U937 (c), ␣v␤3-K562 (d), and ␤3-CHO cells (e). The concentration of Cmpd21 in d and e is 50 M. Data are shown as the means Ϯ S.E. of median fluorescent intensity (MFI) of three independent experiments.
ligands for binding to site 1. To address this question, we determined the effect of sPLA2-IIA as a function of sPLA2-IIA concentrations up to 500 g/ml. The binding of H120 to ␣4-CHO cells was maximum at 20 g/ml sPLA2-IIA and then reduced as sPLA2-IIA concentration increases (Fig. 8 ). This suggests that 1) sPLA2-IIA at low concentrations binds to site 2 of closed ␣4␤1 (site 1 closed, site 2 open) and activates ␣4␤1 (site 1 open), and 2) when site 2 is saturated with sPLA2-IIA, sPLA2-IIA competes with H120 for binding to site 1 (open) and reduces the binding of H120.
DISCUSSION
The present study establishes that sPLA2-IIA activates integrins ␣v␤3, ␣4␤1, and ␣5␤1 through direct binding to site 2. sPLA2-IIA activated recombinant soluble ␣v␤3 in cell-free conditions, suggesting that inside-out signals or other molecules are not involved. This process does not include catalytic activity or receptor binding of sPLA2-IIA as mutating the catalytic center or receptor-binding site of sPLA2-IIA did not affect sPLA2-IIA-mediated integrin activation. sPLA2-IIA induced integrin activation through binding to site 2 is a novel mechanism of integrin activation and proinflammatory action by sPLA2-IIA. sPLA2-IIA may activate other integrins through direct binding.
sPLA2-IIA-mediated integrin activation happens in biological fluids (at least in tears). In the present study Ͼ5 g/ml sPLA2-IIA were required to detect sPLA2-IIA-induced integrin activation. Notably, the concentration of sPLA2-IIA is exceptionally high in human tears (26 -28) . In normal subjects the concentration of sPLA2-IIA in tears is 54.5 Ϯ 33.9 g/ml, one of the highest levels of sPLA2-IIA reported in any normal human secretions (29) . Therefore, integrin activation by sPLA2-IIA happens at least in tears. sPLA2-IIA appears to be secreted by both the lacrimal glands and the goblet cells of conjunctival epithelia (26, 30) . Because sPLA2-IIA is bactericidal and kills Listeria at much lower concentrations (Ͻ0.1 nM), it is possible that the primary functions of sPLA2-IIA at such high concentrations in tears might be integrin activation. It is likely that sPLA2-IIA in tears may play a role in enhancing immune response to bacterial pathogens through local integrin activation in tears or perhaps in other tissues. Serum levels of sPLA2-IIA are increased only up to 1 g/ml during systemic inflammation (2, 3) . sPLA2-IIA may not effectively activate integrins at these concentrations. It is, however, possible that sPLA2-IIA may be highly concentrated in diseased tissues in chronic inflammation or on the cell surface through binding to proteoglycans.
The sPLA2-IIA-induced integrin activation is expected to enhance interaction between cells and extracellular matrix (e.g. fibrinogen and fibronectin) and thereby induce massive prolif- sPLA2-IIA Activates Integrins erative signals. Because integrins are involved in growth factor signaling through cross-talk with growth factor receptors, sPLA2-IIA-induced integrin activation is also expected to enhance cellular responsiveness to growth factors. We have reported that integrins cross-talk with several growth factor receptors through direct binding to growth factors (e.g. fibroblast growth factor-1 (24, (31) (32) (33) , insulin-like growth factor-1 (34 -37), neuregulin-1 (38) , and fractalkine (18)). We propose that sPLA2-IIA-induced integrin activation indirectly affects intracellular signaling by these growth factors through enhancing integrin binding to growth factors.
We establish that site 2 is involved in integrin activation by sPLA2-IIA (the current study) and FKN-CD (19) (Fig. 9 ). This is a new mechanism of integrin activation. It has previously been reported that the binding of a RGD-mimetic peptide induces changes in the tertiary structure of ␣v␤3 (39) and ␣IIb␤3 (40) in the ␤3 I-like domain. RGD or ligand-mimetic peptides activate purified, non-activated ␣IIb␤3 (41) and ␣v␤3 (42) . This process does not require inside-out signal transduction, and it appears that RGD or ligand-mimetic peptide triggers conformational changes that lead to full activation of integrins. These findings suggest that these peptides enhance integrin affinity by conformational changes in the headpiece possibly through additional ligand-binding sites in the integrin (41) . A previous study suggests that there are two RGD-binding sites in integrin ␣IIb␤3 and that one binding site acts as an allosteric site based on binding kinetic studies (43) . Also, another study suggests that two distinct cyclic RGD-mimetic peptides can simultaneously bind to distinct sites in ␣IIb␤3, and the estimated distance between two ligand-binding sites is about 6.1 Ϯ 0.5 nm (44) . The possible allosteric ligand-binding site has not been pursued probably because the ␣v␤3 structure (ligand occupied, openheadpiece) contains only one RGD-binding site (39) . In our docking model the distance between site 1 and site 2 is about 6 nm. Thus, the position of site 2 is consistent with the previous FIGURE 7. sPLA2-IIA enhances the binding of the RGD-containing fibronectin fragment (FN8 -11) to ␣5␤1 through binding to site 2. sPLA2-IIA at 20 g/ml and FN8 -11 at 20 g/ml were used if not indicated otherwise. a and b, specific binding of sPLA2-IIA to integrin ␣5␤1. FITC-labeled sPLA2-IIA (10 g/ml) was incubated with K562 cells (a) or U937 cells (b) in the presence of mouse IgG, KH72 (anti-␣5 mAb), SG73 (anti-␣4 mAb), or 7E3 (anti-␤3 mAb) (10 g/ml). Bound FITC was measured using flow cytometry. Data are shown as the means Ϯ S.E. of median fluorescent intensity (MFI) of three independent experiments. c, Comp21 suppresses sPLA2 binding to ␣5␤1. Adhesion of K562 cells to sPLA2-IIA (coating concentration 10 g/ml) was measured in the presence of Cmpd21. Data are shown as the means Ϯ S.E. of the % adhesion of three independent experiments. d-f, the effect of sPLA2-IIA mutants on the binding of FITC-FN8 -11 was measured in U937 cells (d), K562 cells (e), and CHO cells (f). Data are shown as the means Ϯ S.E. of median fluorescent intensity of three independent experiments. FITC-sPLA2-IIA was used at 20 g/ml if not indicated otherwise. g-i, the binding of FITC-FN8 -11 to U937 cells (g), K562 cells (h), or CHO cells (i) was measured in the presence of S2-␤1 peptide. Data are shown as the means Ϯ S.E. of median fluorescent intensity of three independent experiments. j-l, the binding of FITC-FN8 -11 to U937 cells (j), K562 cells (k), or CHO cells (l) was measured in the presence of Cmpd21. Data are shown as the means Ϯ S.E. of median fluorescent intensity of three independent experiments. We propose a model, in which sPLA2-IIA binds to site 2 of inactive/closedheadpiece integrins and induces conformational changes and enhance ligand binding to site 1 (the classical RGD-binding site). This activation is blocked by a peptide that is derived from site 2 or a small compound (Cmpd21) that binds to the integrin-binding site of sPLA2-IIA. JANUARY 2, 2015 • VOLUME 290 • NUMBER 1 JOURNAL OF BIOLOGICAL CHEMISTRY 269 report. Based on previous studies it is likely that the newly identified site 2 has ligand specificity that overlaps with that of site 1, interacts with integrin ligands other than FKN-CD (e.g. RGD), and is potentially involved in integrin regulation in an allosteric mechanism. It is reasonable to assume that FKN-CD or sPLA2-IIA binding to site 2 induces conformational changes in integrins. We suspect that other proteins also bind to site 2 and affect integrin functions. Also it is likely that integrins other than ␣v␤3, ␣4␤1, and ␣5␤1 are activated by site 2-mediated mechanism. It would be interesting to address this question in future studies.
sPLA2-IIA Activates Integrins
It is unclear if sPLA2-IIA-induced integrin activation requires global conformational changes in integrins. In current models of integrin activation, activation of ␤1 integrins induces a swing-out movement of the hybrid domain and exposes epitopes recognized by activation-dependent antibodies (antihuman ␤1 HUTS4 and HUTS21) (45) . The HUTS4 and HUTS21 epitopes are located in the hybrid domain of ␤1 (46, 47) . In our preliminary experiments sPLA-IIA did not change reactivity of ␤1 integrins to HUTS4 and HUTS21 in U937, K562, and ␣4-K562 cells in RPMI1640 medium under the conditions in which sPLA2-IIA enhanced the binding of ␤1 integrins to ligands. It is possible that the binding of sPLA2-IIA to site 2 induces only local conformational changes within the headpiece of integrins. Interestingly, the open-headpiece (PDB code 1L5G) and closed-headpiece (PDB code 1JV2) conformations of ␣v␤3 are very similar (39, 48) . Surprisingly, the docking simulation distinguished the two conformations and predicted the position of site 2 in the closed-headpiece form. We showed that sPLA2-IIA (the current study) and FKN-CD (19) actually bind to site 2 and the binding of sPLA2-IIA and FKN to site 2 is required for integrin activation using the peptides from site 2. It is likely that integrins that are activated by sPLA2-IIA and FKN-CD through site 2 have conformations similar to the open-headpiece ␣v␤3 that has no global conformational changes compared with the closed-headpiece form. The open-and closed-headpiece conformations of ␣v␤3 may really reflect the fact that integrins can be activated without global conformational changes through allosteric mechanism.
The site 2-derived integrin peptides were used for establishing that sPLA2-IIA really binds to site 2, and the interaction is involved in integrin activation. We studied if S2-␤1 peptide acts as an antagonist for sPLA2-IIA-mediated proinflammatory signals (supplemental Fig. S2 ). S2-␤1 peptide suppressed chemotaxis induced by sPLA2-IIA. Although it is unclear if S2-␤1 peptide suppressed the binding of sPLA2-IIA to site 1 or site 2 at this point, the results suggest that S2-␤1 peptide has potential as a therapeutic.
Specific inhibitors of sPLA2-IIA catalytic activity S-5920/ LY315920Na and S-3013/LY333013 failed to demonstrate a significant therapeutic effect in rheumatoid arthritis (49) and asthma (50) . Our previous study suggests that sPLA2-IIA-integrin interaction may be a potential target for chronic inflammatory diseases (14) . Cmpd21 was screened for its ability to bind to the integrin-binding site of sPLA2-IIA (15) . Indeed Cmpd21 suppressed the binding of sPLA2-IIA to integrins, and in the present study we demonstrated that Cmpd21 suppressed the sPLA2-IIA-induced integrin activation via site 2 as well. It would be interesting to study if Cmpd21 or its variants suppress inflammation in vivo in future studies.
